Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating restated by stock analysts at Jefferies Group in a research report issued on Tuesday. They presently have a $262.00 price objective on the biopharmaceutical company’s stock. Jefferies Group’s target price indicates a potential upside of 28.78% from the stock’s previous close.

Several other analysts also recently weighed in on SHPG. Morgan Stanley restated an “overweight” rating on shares of Shire PLC in a report on Friday, June 3rd. Piper Jaffray Cos. reiterated a “neutral” rating and issued a $174.00 target price on shares of Shire PLC in a report on Friday, July 15th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Leerink Swann reiterated an “outperform” rating and issued a $225.00 target price on shares of Shire PLC in a report on Thursday, May 26th. Finally, Stifel Nicolaus initiated coverage on shares of Shire PLC in a report on Thursday, May 26th. They issued a “buy” rating and a $230.00 target price for the company. Four research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $230.67.

Shire PLC (NASDAQ:SHPG) opened at 203.44 on Tuesday. The company has a market cap of $60.60 billion, a PE ratio of 42.28 and a beta of 1.11. The stock has a 50 day moving average of $195.66 and a 200 day moving average of $183.51. Shire PLC has a 52 week low of $147.60 and a 52 week high of $231.32.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/jefferies-group-reaffirms-buy-rating-for-shire-plc-shpg.html

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.35. The firm earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm’s quarterly revenue was up 55.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.63 earnings per share. Equities research analysts predict that Shire PLC will post $12.93 EPS for the current fiscal year.

The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be paid a $0.139 dividend. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. increased its position in Shire PLC by 11.2% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 5,009 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 506 shares in the last quarter. BlackRock Fund Advisors boosted its stake in shares of Shire PLC by 10.0% in the first quarter. BlackRock Fund Advisors now owns 591,458 shares of the biopharmaceutical company’s stock valued at $101,672,000 after buying an additional 53,889 shares during the last quarter. Agur Provident & Training Funds Management Ltd. bought a new stake in shares of Shire PLC during the first quarter valued at about $1,622,000. Connable Office Inc. boosted its stake in shares of Shire PLC by 17.5% in the first quarter. Connable Office Inc. now owns 2,205 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 328 shares during the last quarter. Finally, Ngam Advisors L.P. boosted its stake in shares of Shire PLC by 22.8% in the first quarter. Ngam Advisors L.P. now owns 34,151 shares of the biopharmaceutical company’s stock valued at $5,870,000 after buying an additional 6,333 shares during the last quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.